Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 16/20 | 0.54 |
| ▸ | TUBB | P07437 | 16/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 16/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 16/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 16/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 16/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 16/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 16/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 16/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 16/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 16/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 16/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 16/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 16/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 16/20 | 0.54 |
| ▸ | KDR | P35968 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950183 | 0.95 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4173428 | 0.84 | KDR (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4169664 | 0.76 | BRD4 (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4185580 | 0.74 | HTR6 (0.36) | KDR | |
| SCHEMBL4181451 | 0.72 | TUBB4A (0.79) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4532299 | 0.71 | KDR (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4172628 | 0.71 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4171138 | 0.70 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4181099 | 0.70 | KDR (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4169660 | 0.70 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | TUBB4A 777/4885TUBB 766/4885TUBA3C 422/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | TUBB4A 777/4885TUBB 766/4885TUBA3C 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.